New genetic variants that are associated with increased risk of prostate cancer have been identified

September 21, 2009

Moffitt Cancer Center Research Involved in Nature Genetics Study

Tampa, FL – Two studies led by Rosalind Eeles, Julius Gudmundsson and colleagues surveyed the genomes of thousands of men with prostate cancer, which is the second most common cancer in men and affects approximately 25 per 100,000 men worldwide. Together, these studies identified eight new genetic loci that are associated with increased risk of prostate cancer. In addition, the studies report the identification of two new variants on 8q24 that confer risk of prostate cancer.

           An area on 8q24 has been associated with breast, colon, and bladder cancer. Although this region contains no known protein-coding genes, the oncogene MYC is located next to this region. Douglas Easton and colleagues report a comprehensive analysis of 8q24 and identify two new regions in 8q24 that are associated with risk of prostate cancer. Meredith Yeager and colleagues also independently identified one of same new risk variants at 8q24 as Easton. Altogether, the studies emphasize the need for more research on the 8q24 locus, since future discoveries will likely be relevant to multiple types of cancer.

About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida, Moffitt Cancer Center  is an NCI Comprehensive Cancer Center - a designation that recognizes Moffitt’s excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.